PJB-2023-619
Therapeutic potential of Eichhornia crassipes: analgesic and antidiarrheal effects in preclinical and in silico studies
Fayaz Asad, Naheed Fazal, Shazia Sakhi, Sabrina Shahid, Muzammil Shah, Mamoona Bibi, Imtiaz Ahmad, Imran Khan, Muhammad Hamayun, Shumaila Siraj and Sajid Ali
Abstract
Eichhornia crassipes is a plant known for its medicinal properties, and its active metabolites help explain its medicinal properties. Its pharmacological mechanisms and potential medical uses are being investigated through preclinical research and in silico analysis. In this study, we investigated the analgesic and anti-diarrheal properties of E. crassipes extracts in animal models and examined the effects of phytochemicals on cholinergic and COX-2 receptors by In-silico analysis. Animal models were used to assess the analgesic and anti-diarrheal effects of extracts from E. crassipes. In-silico experiments were also conducted to examine the impact of various phytochemicals on acetylcholine and COX-2 receptors. The effectiveness of 7,9-Di-tert-butyl-1-oxaspiro (4.5) deca-6,9-diene-2,8-dione and stigmasterol were compared to the standard drug Loperamide, and the pharmacokinetic characteristics of docked phytochemicals were also investigated. The research showed that extracts from E. crassipes have significant potential as pain relievers and anti-diarrheal agents in animals. Through computer simulations, certain plant compounds were found to interact well with cholinergic and COX-2 receptors. Specifically, stigmasterol and 7,9-Di-tert-butyl-1-oxaspiro (4.5) deca-6,9-diene-2,8-dione were just as effective as Loperamide. Additionally, the simulated plant compounds showed promising pharmacokinetic properties. The findings of this study traditional the conventional therapeutic practices of E. crassipes and illustrate the potential contribution of dynamic metabolites to its therapeutic pursuits. Considerable analgesic and anti-diarrheal potentials observed in animal models and in silico studies suggest that certain phytochemicals have promising impacts on cholinergic and COX-2 receptors.